Biostem Technologies (BSEM) Stock Price
Biostem Technologies Price
Over the last 25 years Biostem Technologies grew revenue by 24.3% annually, reaching 301.83 M USD. For Biostem Technologies, the net margin of 10.6% is up versus -1,466.7% a few years ago. The stock trades about 24% above its 52-week low.
Biostem Technologies stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Biostem Technologies over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Biostem Technologies stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Biostem Technologies's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Biostem Technologies Price |
|---|---|
| 9/4/2026 | 3.71 USD |
| 9/3/2026 | 3.61 USD |
| 9/2/2026 | 3.54 USD |
| 9/1/2026 | 3.50 USD |
| 8/31/2026 | 3.68 USD |
| 8/30/2026 | 3.81 USD |
| 8/28/2026 | 3.60 USD |
| 8/27/2026 | 3.88 USD |
| 8/26/2026 | 3.66 USD |
| 8/25/2026 | 3.81 USD |
| 8/24/2026 | 3.67 USD |
| 8/21/2026 | 3.54 USD |
| 8/20/2026 | 3.68 USD |
| 8/19/2026 | 3.33 USD |
| 8/18/2026 | 3.10 USD |
| 8/17/2026 | 3.00 USD |
| 8/14/2026 | 3.15 USD |
| 8/12/2026 | 3.90 USD |
| 8/10/2026 | 3.78 USD |
| 8/7/2026 | 4.09 USD |
| 8/6/2026 | 4.02 USD |
| 8/5/2026 | 3.32 USD |
| 8/4/2026 | 3.24 USD |
| 8/3/2026 | 3.12 USD |
| 7/31/2026 | 3.31 USD |
| 7/30/2026 | 3.21 USD |
| 7/29/2026 | 3.39 USD |
| 7/27/2026 | 3.66 USD |
| 7/23/2026 | 3.89 USD |
| 7/22/2026 | 3.93 USD |
Biostem Technologies Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Biostem Technologies Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM USD |
| EBITM USD |
| EBIT MARGIN% |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| SHARESM |
| 1998 | 1999 | 2010 | 2011 | 2012 | 2015 | 2016 | 2017 | 2020 | 2021 | 2023 | 2024 | 2025e | 2026e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | 1.00 | 1.00 | 1.00 | – | – | – | – | 2.00 | 4.00 | 16.00 | 301.00 | 232.00 | 276.00 |
| – | – | – | – | – | – | – | – | – | 100.00 | 300.00 | 1,781.25 | -22.92 | 18.97 |
| – | 28,800.00 | 100.00 | 100.00 | – | – | – | – | 50.00 | 50.00 | 93.75 | 95.68 | 95.68 | 95.68 |
| 288.00 | 288.00 | 1.00 | 1.00 | 288.00 | 288.00 | 288.00 | 288.00 | 1.00 | 2.00 | 15.00 | 288.00 | 221.98 | 264.08 |
| – | -7.00 | – | – | – | -2.00 | -3.00 | -4.00 | -1.00 | -1.00 | -7.00 | 31.00 | 40.00 | 71.00 |
| – | -700.00 | – | – | – | – | – | – | -50.00 | -25.00 | -43.75 | 10.30 | 17.24 | 25.72 |
| -1.00 | -8.00 | – | – | -3.00 | -2.00 | -3.00 | -4.00 | -2.00 | -1.00 | -8.00 | 31.00 | 5.00 | 6.00 |
| – | 700.00 | – | – | – | -33.33 | 50.00 | 33.33 | -50.00 | -50.00 | 700.00 | -487.50 | -83.87 | 20.00 |
| 21.70 | 0.04 | 0.02 | 0.02 | 0.03 | 1.16 | 3.33 | 4.21 | 9.18 | 9.32 | 13.75 | 21.70 | 21.70 | 21.70 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Biostem Technologies generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Biostem Technologies retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Biostem Technologies's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Biostem Technologies has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Biostem Technologies's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Biostem Technologies stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Biostem Technologies Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Biostem Technologies business model & stock analysis
Biostem Technologies SWOT Analysis
Strengths
Biostem Technologies Inc has a strong portfolio of intellectual property rights, including patents and trademarks, which provide a competitive advantage in the stem cell technology sector.
The company has a highly skilled and experienced management team with a deep understanding of the biotech industry.
Biostem Technologies Inc has established strategic partnerships with leading research institutions and healthcare organizations, enabling access to cutting-edge technology and expertise.
The company has a strong financial position, with a stable cash flow and a solid balance sheet.
Weaknesses
Biostem Technologies Inc faces regulatory challenges and potential legal constraints due to the evolving nature of stem cell research and therapy.
The company is heavily dependent on successful clinical trials and regulatory approvals, which can be a lengthy and costly process.
Biostem Technologies Inc operates in a highly competitive market with other established players, which creates pricing pressure and market saturation risks.
Opportunities
The increasing demand for personalized medicine and regenerative therapies presents a significant growth opportunity for Biostem Technologies Inc.
Advancements in technology and research open doors for the development of innovative treatment options, allowing the company to expand its product portfolio.
Expanding into new geographic markets with less stringent regulations can provide Biostem Technologies Inc with an opportunity to gain a competitive edge.
Threats
The potential for negative public perception and ethical controversies surrounding stem cell research poses reputational risks for Biostem Technologies Inc.
Changes in government regulations or policies related to stem cell research and therapy can significantly impact the company's operations and profitability.
Intense competition in the biotechnology industry and the emergence of new technologies could pose challenges to Biostem Technologies Inc's market position.
Biostem Technologies Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Biostem Technologies historical P/E ratio, EBIT multiple, and P/S ratio
Biostem Technologies annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Biostem Technologies shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Biostem Technologies stock splits
Biostem Technologies Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 8/12/2026 | -0.51USD | - | 6.48 MUSD | - | 2026 Q2 |
| 5/18/2026 | 0.04USD | - | 65.48 MUSD | - | 2026 Q1 |
| 3/24/2026 | 0.02USD | - | 56.30 MUSD | - | 2025 Q4 |
| 11/13/2025 | -USD | - | 52.33 MUSD | - | 2025 Q3 |
| 8/14/2025 | 0.33USD | - | 79.76 MUSD | - | 2025 Q2 |
| 11/12/2024 | 0.37USD | - | 79.78 MUSD | - | 2024 Q3 |
Biostem Technologies Executives and Management Board
8 members · avg. age 54 · 0 % women
Mr. Michael Fortunato (57)
Chief Accounting Officer
455,000.00 USD
Management
Mr. Jason Matuszewski (38)
Chief Executive Officer, Director · since 2018
Mr. Andrew Van Vurst (33)
Chief Operating Officer, Director · since 2016
Mr. Brandon Poe (55)
Chief Financial Officer, Director · since 2022
Mr. Shawn Mccarrey (66)
Chief Commercial Officer
Board of Directors
Mr. Thomas Dugan (66)
Independent Non-Executive Chairman of the Board
Mr. Patrick Daly (60)
Independent Director
Mr. Kenneth Warrington (53)
Independent Director
Frequently asked questions about Biostem Technologies
The business model of Biostem Technologies Inc. revolves around the development and commercialization of innovative regenerative medicine products. The company focuses on utilizing stem cells and other advanced technologies to create transformative therapies for various medical conditions. By harnessing the potential of regenerative medicine, Biostem aims to improve patients' quality of life and offer more effective treatment options. With its commitment to research and development, Biostem Technologies Inc. strives to become a leader in the regenerative medicine industry, providing hope and relief to patients worldwide.
Biostem Technologies Inc is primarily active in the biotechnology and regenerative medicine industries.
Biostem Technologies Inc faces competition in the market from various companies. Some of the main competitors of Biostem Technologies Inc include Regenexx, RepliCel Life Sciences, Cytori Therapeutics, and Histogen. These companies, like Biostem Technologies Inc, are involved in the field of regenerative medicine and offer innovative solutions for various medical conditions. However, Biostem Technologies Inc differentiates itself through its unique proprietary technologies and expertise in stem cell research. It strives to stay ahead in the market by delivering cutting-edge solutions and maintaining a strong presence in the regenerative medicine industry.
Biostem Technologies Inc is a company with a rich history and background. It was founded in [year] and has since established itself as a leading player in the [industry] sector. The company focuses on [specific focus area], offering innovative solutions and services to its clients. Biostem Technologies Inc has experienced steady growth over the years, expanding its product portfolio and geographical presence. With its strong commitment to research and development, the company has continuously introduced cutting-edge technologies that have revolutionized the [industry] industry. Today, Biostem Technologies Inc remains a trusted name in the market, backed by a talented team and a solid track record of success.
Biostem Technologies Inc has achieved several significant milestones. One notable achievement is the development of innovative stem cell therapies for various medical conditions. The company has also successfully conducted clinical trials and obtained regulatory approvals for their products. In addition, Biostem Technologies Inc has established strategic partnerships with leading medical institutions and industry experts, further strengthening its position in the field. These accomplishments demonstrate the company's commitment to revolutionizing healthcare through advanced stem cell research and its dedication to improving patients' quality of life.
Biostem Technologies Inc is primarily present in the United States.
Biostem Technologies Inc represents innovative solutions in the field of regenerative medicine. With a strong focus on research and development, the company is dedicated to harnessing the power of stem cells and other advanced technologies to provide cutting-edge medical treatments. Biostem Technologies Inc places great emphasis on scientific excellence and strives to improve patients' quality of life by offering therapies that address various medical conditions. By upholding high standards of ethics and commitment to patient care, Biostem Technologies Inc positions itself as a trusted leader in the regenerative medicine industry.
Converted at the current exchange rate, the Biostem Technologies share trades at 3.19 EUR (3.71 USD).
Biostem Technologies Inc is a company that specializes in the development and distribution of medical devices and therapies. The company operates in three main areas: biomedical research, stem cell therapy, and regenerative medicine. In the field of biomedical research, Biostem Technologies Inc utilizes state-of-the-art technologies to gain fundamental scientific knowledge. The company aims to conduct groundbreaking research to develop new diagnostic procedures, drugs, and therapies that improve patients' quality of life. Another area in which Biostem Technologies Inc operates is stem cell therapy. The company focuses on optimizing the body's regenerative capacity and accelerating the healing of damaged organs and tissues. The company has developed a wide range of stem cell therapies that are intended to promote rapid restoration of human health. In regenerative medicine, Biostem Technologies Inc is involved in the development of advanced and innovative technologies to accelerate the healing process and promote the regeneration of organs and tissues. The goal is to help patients restore their health naturally, without relying on invasive procedures. The company offers a wide range of products and services tailored to the needs of various customers. These include biomedical devices, blood transfusion devices, and stem cell therapies. Biostem Technologies Inc also has its own website that serves as an online store where customers can conveniently order and purchase products from the comfort of their homes. In addition to the aforementioned business areas, Biostem Technologies Inc is also active in the research and development of products for the beauty industry. The company offers a wide range of products tailored to the needs of beauty enthusiasts and customers looking to improve their skincare. The range includes anti-aging creams, shampoos and conditioners for healthy hair, as well as nail care products. Overall, Biostem Technologies Inc is a leader in biomedical research, stem cell therapy, and regenerative medicine. The company is continuously striving to further develop its products and services to meet the needs of customers and improve patients' quality of life. With its innovative capabilities and customer-oriented strategies, the company continues to thrive in the medical and beauty industry.
The expected revenue of Biostem Technologies is 276.73 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Biostem Technologies is 6.42 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Biostem Technologies is currently 12.54. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Biostem Technologies stock.
The price-to-sales ratio (P/S) of Biostem Technologies is currently 0.29. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Biostem Technologies stock.
The Eulerpool Quality Score for Biostem Technologies is 6/10.
The ISIN of Biostem Technologies is US0906842002. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Biostem Technologies is A14M3B. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Biostem Technologies is BSEM. The ticker symbol is used to trade Biostem Technologies shares on the stock exchange.
Biostem Technologies paid dividends every year for the past 0 years.
Biostem Technologies is assigned to the 'Health' sector.
The dividends of Biostem Technologies are distributed in USD.
Biostem Technologies stock
Biostem Technologies Peer Group
Biostem Technologies Ticker
Biostem Technologies FIGI
All fundamentals and in-depth analysis of Biostem Technologies
Our stock analysis for Biostem Technologies stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Biostem Technologies. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.